LifeCore Biomedical Files 8-K on Financials

Ticker: LFCR · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1005286

Lifecore Biomedical, Inc. \De\ 8-K Filing Summary
FieldDetail
CompanyLifecore Biomedical, Inc. \De\ (LFCR)
Form Type8-K
Filed DateApr 1, 2024
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, filing

Related Tickers: LFCR

TL;DR

LifeCore Biomedical dropped an 8-K on financials, check it out.

AI Summary

LifeCore Biomedical, Inc. filed an 8-K on April 1, 2024, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and exhibits. The company, formerly known as Landec Corp, is incorporated in Delaware and headquartered in Chaska, Minnesota.

Why It Matters

This filing provides investors with crucial updates on LifeCore Biomedical's financial performance and condition, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Players & Entities

  • LIFECORE BIOMEDICAL, INC. (company) — Registrant
  • LANDEC CORP (company) — Former company name
  • April 1, 2024 (date) — Date of earliest event reported
  • 000-27446 (other) — SEC file number
  • 94-3025618 (other) — IRS Employer Identification No.

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of LifeCore Biomedical, Inc., and to include financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on April 1, 2024.

What is the current company name and its former name?

The current company name is LifeCore Biomedical, Inc., and its former name was Landec Corp.

In which state is LifeCore Biomedical, Inc. incorporated?

LifeCore Biomedical, Inc. is incorporated in Delaware.

What is the principal executive office address and phone number?

The principal executive office is located at 3515 Lyman Boulevard, Chaska, Minnesota 55318, and the telephone number is (952) 368-4300.

Filing Stats: 654 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-04-01 08:07:33

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On April 1, 2024, Lifecore Biomedical, Inc., a Delaware corporation (the "Company") issued a press release announcing a business update, including preliminary estimates of certain consolidated financial data of Lifecore as of and for the fiscal quarters ended August 27, 2023, November 26, 2023, and February 24, 2024, and the nine months ended February 24, 2024 (the "Press Release"). A copy of the Press Release furnished as Exhibit 99.1 hereto and is incorporated herein by reference. This information, including the information contained in the press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing. Additionally, on April 1, 2024, the Company made available on its website a supplementary investor presentation, which includes certain supplemental information related to the topics reflected in the Press Release (the "Supplemental Presentation"). A copy of the Supplemental Presentation is furnished as Exhibit 99.2 hereto and is incorporated herein by reference. This information, including the information contained in the Supplemental Presentation, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished as part of this report: Exhibit No. Description 99.1 Press Release, dated April 1, 2024 99.2 Supplemental Presentation, dated April 1, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 1, 2024 LIFECORE BIOMEDICAL, INC. By: /s/ John D. Morberg John D. Morberg Executive Vice President and Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.